Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cilostamide is a potent and selective small molecule inhibitor of phosphodiesterase 3 (PDE3), an enzyme that regulates intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by catalyzing their hydrolysis. By specifically blocking PDE3, cilostamide increases cAMP concentrations, which modulates various downstream signaling pathways. In experimental cardiology, it is frequently used to enhance or 'unmask' the positive inotropic effects of G-protein coupled receptor (GPCR) agonists in human and animal atrial tissues. In reproductive biology, it is utilized as a research tool to maintain meiotic arrest in cumulus-oocyte complexes during in vitro culture, supporting oocyte development and fertility preservation techniques. Recent preclinical research has also identified cilostamide as a potential therapeutic agent for preventing liver injury during long-term supercooling preservation by inhibiting the PDE3B-cAMP-autophagy axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cilostamide.